ASTELLAS OBTAINS RIGHTS FOR ANEMIA DRUGS IN EUROPE, OTHER AREAS.
Publication: AsiaPulse News
Publication Date: 01-MAY-06
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
TOKYO, May 1 Asia Pulse - Astellas Pharma Inc. (TSE:4503) said Friday that it has acquired from U.S. pharmaceutical firm FibroGen Inc. exclusive rights for the development and marketing of investigational oral therapies for anemia in Europe, Russia, the Middle East and South Africa.
The deal is valued at...
Read the full article for free courtesy of your local library.
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
